Pyruvate kinase M2 and cancer: An updated assessment

FEBS Letters

Volumn 588, Issue 16, 2014, Pages 2685-2692

  Iqbal, Mohd Askandar ^a,c   Gupta, Vibhor ^a,d   Gopinath, Prakasam ^a   Mazurek, Sybille ^b   Bamezai, Rameshwar N K ^a  

^a JAWAHARLAL NEHRU UNIVERSITY   (India)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c UNIVERSITY OF TEXAS   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cancer metabolism; PKM2; Warburg effect

Indexed keywords

3 PHOSPHOGLYCERIC ACID; CYCLIN D1; DIHYDROXYACETONE PHOSPHATE; DIOXYGENASE; FRUCTOSE 6 PHOSPHATE; GLUCOSE; GLUCOSE 6 PHOSPHATE; GLYCERALDEHYDE 3 PHOSPHATE; GROWTH FACTOR; HEXOSE PHOSPHATE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INSULIN; JUMONJI C DOMAIN CONTAINING DIOXYGENASE; LIOTHYRONINE; OCTAMER TRANSCRIPTION FACTOR 4; PYRUVATE KINASE; PYRUVATE KINASE ISOENZYME M 2; UNCLASSIFIED DRUG;

ACETYLATION; ANAEROBIC GLYCOLYSIS; BREAST TUMOR; CANCER CELL; CARCINOGENESIS; CELL CYCLE PROGRESSION; COMPLEX FORMATION; DNA METHYLATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; ENZYME STRUCTURE; GENE; GENE EXPRESSION; GLYCOLYSIS; HETEROZYGOSITY; HUMAN; LOSS OF FUNCTION MUTATION; NONHUMAN; PKM GENE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REVIEW; RNA INTERFERENCE; RNA SPLICING; TRANSACTIVATION; UPREGULATION;

CANCER METABOLISM; PKM2; WARBURG EFFECT;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOLYSIS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN MULTIMERIZATION; PYRUVATE KINASE;

EID: 84905097406     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2014.04.011     Document Type: Review

References (94)

1. O. Warburg, K. Posener, and E. Negelein Über den Stoffwechsel der Carcinomzelle Biochem. Ztschr. 152 1924 309 344
2. O. Warburg On the origin of cancer cells Science 123 1956 309 314
3. C.V. Dang, and G.L. Semenza Oncogenic alterations of metabolism Trends Biochem. Sci. 24 1999 68 72
4. P.P. Hsu, and D.M. Sabatini Cancer cell metabolism: Warburg and beyond Cell 134 2008 703 707
5. S.S. Gambhir Molecular imaging of cancer with positron emission tomography Nat. Rev. Cancer 2 2002 683 693
6. R.A. Hawkins, and M.E. Phelps PET in clinical oncology Cancer Metastasis Rev. 7 1988 119 142
7. W.A. Weber, N. Avril, and M. Schwaiger Relevance of positron emission tomography (PET) in oncology Strahlenther. Onkol. 175 1999 356 373
8. K. Golman, R.I. Zandt, M. Lerche, R. Pehrson, and J.H. Ardenkjaer-Larsen Metabolic imaging by hyperpolarized 13C magnetic resonance imaging for in vivo tumor diagnosis Cancer Res. 66 2006 10855 10860
9. J. Kurhanewicz, D.B. Vigneron, K. Brindle, E.Y. Chekmenev, A. Comment, C.H. Cunningham, R.J. Deberardinis, G.G. Green, M.O. Leach, S.S. Rajan, R.R. Rizi, B.D. Ross, W.S. Warren, and C.R. Malloy Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research Neoplasia 13 2011 81 97
10. M.G. Vander Heiden, L.C. Cantley, and C.B. Thompson Understanding the Warburg effect: the metabolic requirements of cell proliferation Science 324 2009 1029 1033
11. F. Hirschhaeuser, U.G. Sattler, and W. Mueller-Klieser Lactate: a metabolic key player in cancer Cancer Res. 71 2011 6921 6925
12. Z. Husain, Y. Huang, P. Seth, and V.P. Sukhatme Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells J. Immunol. 191 2013 1486 1495
13. K. Fischer, P. Hoffmann, S. Voelkl, N. Meidenbauer, J. Ammer, M. Edinger, E. Gottfried, S. Schwarz, G. Rothe, S. Hoves, K. Renner, B. Timischl, A. Mackensen, L. Kunz-Schughart, R. Andreesen, S.W. Krause, and M. Kreutz Inhibitory effect of tumor cell-derived lactic acid on human T cells Blood 109 2007 3812 3819
14. R.A. Gatenby, and R.J. Gillies Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 4 2004 891 899
15. S.Y. Lunt, and M.G. Vander Heiden Aerobic glycolysis: meeting the metabolic requirements of cell proliferation Annu. Rev. Cell Dev. Biol. 27 2011 441 464
16. S. Mazurek Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells Int. J. Biochem. Cell Biol. 43 2011 969 980
17. S. Mazurek, C.B. Boschek, F. Hugo, and E. Eigenbrodt Pyruvate kinase type M2 and its role in tumor growth and spreading Semin. Cancer Biol. 15 2005 300 308
18. W. Luo, H. Hu, R. Chang, J. Zhong, M. Knabel, R. O'Meally, R.N. Cole, A. Pandey, and G.L. Semenza Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1 Cell 145 2011 732 744
19. W. Yang, Y. Xia, H. Ji, Y. Zheng, J. Liang, W. Huang, X. Gao, K. Aldape, and Z. Lu Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation Nature 480 2011 118 122
20. X. Gao, H. Wang, J.J. Yang, X. Liu, and Z.R. Liu Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase Mol. Cell 45 2012 598 609
21. Y. Jiang, X. Li, W. Yang, D.H. Hawke, Y. Zheng, Y. Xia, K. Aldape, C. Wei, F. Guo, Y. Chen, and Z. Lu PKM2 regulates chromosome segregation and mitosis progression of tumor cells Mol. Cell 53 2014 75 87
22. W. Yang, Y. Xia, D. Hawke, X. Li, J. Liang, D. Xing, K. Aldape, T. Hunter, W.K. Alfred Yung, and Z. Lu PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis Cell 150 2012 685 696
23. T. Noguchi, K. Yamada, H. Inoue, T. Matsuda, and T. Tanaka The L- and R-type isozymes of rat pyruvate kinase are produced from a single gene by use of different promoters J. Biol. Chem. 262 1987 14366 14371
24. T. Noguchi, H. Inoue, and T. Tanaka The M1- and M2-type isozymes of rat pyruvate kinase are produced from the same gene by alternative RNA splicing J. Biol. Chem. 261 1986 13807 13812
25. H.J. Hacker, P. Steinberg, and P. Bannasch Pyruvate kinase isoenzyme shift from L-type to M2-type is a late event in hepatocarcinogenesis induced in rats by a choline-deficient/dl-ethionine-supplemented diet Carcinogenesis 19 1998 99 107
26. H.R. Christofk, M.G. Vander Heiden, M.H. Harris, A. Ramanathan, R.E. Gerszten, R. Wei, M.D. Fleming, S.L. Schreiber, and L.C. Cantley The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth Nature 452 2008 230 233
27. P. Steinberg, A. Klingelhoffer, A. Schafer, G. Wust, G. Weisse, F. Oesch, and E. Eigenbrodt Expression of pyruvate kinase M2 in preneoplastic hepatic foci of N-nitrosomorpholine-treated rats Virchows Arch. 434 1999 213 220
28. S. Desai, M. Ding, B. Wang, Z. Lu, Q. Zhao, K. Shaw, W.K. Yung, J.N. Weinstein, M. Tan, and J. Yao Tissue-specific isoform switch and DNA hypomethylation of the pyruvate kinase PKM gene in human cancers Oncotarget 2013
29. U. Brinck, E. Eigenbrodt, M. Oehmke, S. Mazurek, and G. Fischer L- and M2-pyruvate kinase expression in renal cell carcinomas and their metastases Virchows Arch. 424 1994 177 185
30. J.D. Dombrauckas, B.D. Santarsiero, and A.D. Mesecar Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis Biochemistry 44 2005 9417 9429
31. C.J. David, M. Chen, M. Assanah, P. Canoll, and J.L. Manley HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer Nature 463 2010 364 368
32. Sun, Q.; Chen, X.; Ma, J.; Peng, H.; Wang, F.; Zha, X.; Wang, Y.; Jing, Y.; Yang, H.; Chen, R.; Chang, L.; Zhang, Y.; Goto, J.; Onda, H.; Chen, T.; Wang, M. R.; Lu, Y.; You, H.; Kwiatkowski, D. & Zhang, H. (2011) Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth, Proc. Natl. Acad. Sci. U.S.A. 108, 4129-4134.
33. D. Schafer, B. Hamm-Kunzelmann, and K. Brand Glucose regulates the promoter activity of aldolase A and pyruvate kinase M2 via dephosphorylation of Sp1 FEBS Lett. 417 1997 325 328
34. R.R. Traxinger, and S. Marshall Insulin regulation of pyruvate kinase activity in isolated adipocytes. Crucial role of glucose and the hexosamine biosynthesis pathway in the expression of insulin action J. Biol. Chem. 267 1992 9718 9723
35. K. Ashizawa, T. Fukuda, and S.Y. Cheng Transcriptional stimulation by thyroid hormone of a cytosolic thyroid hormone binding protein which is homologous to a subunit of pyruvate kinase M1 Biochemistry 31 1992 2774 2778
36. S. Saheki, K. Saheki, and T. Tanaka Changes in pyruvate kinase isozymes of rat small intestine during development and the synergistic effect on them of thyroid and glucocorticoid hormones Enzyme 24 1979 8 17
37. Y. Asai, K. Yamada, T. Watanabe, V.W. Keng, and T. Noguchi Insulin stimulates expression of the pyruvate kinase M gene in 3T3-L1 adipocytes Biosci. Biotechnol. Biochem. 67 2003 1272 1277
38. M.A. Iqbal, F.A. Siddiqui, V. Gupta, S. Chattopadhyay, P. Gopinath, B. Kumar, S. Manvati, N. Chaman, and R.N. Bamezai Insulin enhances metabolic capacities of cancer cells by dual regulation of glycolytic enzyme pyruvate kinase M2 Mol. Cancer 12 2013 72
39. E.J. Gallagher, and D. LeRoith Minireview: IGF, insulin, and cancer Endocrinology 152 2011 2546 2551
40. S. Kress, A. Stein, P. Maurer, B. Weber, J. Reichert, A. Buchmann, P. Huppert, and M. Schwarz Expression of hypoxia-inducible genes in tumor cells J. Cancer Res. Clin. Oncol. 124 1998 315 320
41. H. Lu, R.A. Forbes, and A. Verma Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis J. Biol. Chem. 277 2002 23111 23115
42. M.W. Dewhirst, Y. Cao, and B. Moeller Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response Nat. Rev. Cancer 8 2008 425 437
43. P.C. Lara, M. Lloret, B. Clavo, R.M. Apolinario, L.A. Henriquez-Hernandez, E. Bordon, F. Fontes, and A. Rey Severe hypoxia induces chemo-resistance in clinical cervical tumors through MVP over-expression Radiat. Oncol. 4 2009 29
44. A.L. Lehninger, D.L. Nelson, and M.M. Cox Principles of Biochemistry second ed. 1993 Worth New York
45. R.J. Deberardinis, N. Sayed, D. Ditsworth, and C.B. Thompson Brick by brick: metabolism and tumor cell growth Curr. Opin. Genet. Dev. 18 2008 54 61
46. V. Gupta, and R.N. Bamezai Human pyruvate kinase M2: a multifunctional protein Protein Sci. 19 2010 2031 2044
47. S. Mazurek, H. Grimm, C.B. Boschek, P. Vaupel, and E. Eigenbrodt Pyruvate kinase type M2: a crossroad in the tumor metabolome Br. J. Nutr. 87 Suppl. 1 2002 S23 S29
48. S. Mazurek, H.C. Drexler, J. Troppmair, E. Eigenbrodt, and U.R. Rapp Regulation of pyruvate kinase type M2 by A-Raf: a possible glycolytic stop or go mechanism Anticancer Res. 27 2007 3963 3971
49. K. Ashizawa, M.C. Willingham, C.M. Liang, and S.Y. Cheng In vivo regulation of monomer-tetramer conversion of pyruvate kinase subtype M2 by glucose is mediated via fructose 1,6-bisphosphate J. Biol. Chem. 266 1991 16842 16846
50. T. Hitosugi, S. Kang, M.G. Vander Heiden, T.W. Chung, S. Elf, K. Lythgoe, S. Dong, S. Lonial, X. Wang, G.Z. Chen, J. Xie, T.L. Gu, R.D. Polakiewicz, J.L. Roesel, T.J. Boggon, F.R. Khuri, D.G. Gilliland, L.C. Cantley, J. Kaufman, and J. Chen Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth Sci. Signal. 2 2009 ra73
51. L. Lv, D. Li, D. Zhao, R. Lin, Y. Chu, H. Zhang, Z. Zha, Y. Liu, Z. Li, Y. Xu, G. Wang, Y. Huang, Y. Xiong, K.L. Guan, and Q.Y. Lei Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth Mol. Cell 42 2011 719 730
52. D. Anastasiou, G. Poulogiannis, J.M. Asara, M.B. Boxer, J.K. Jiang, M. Shen, G. Bellinger, A.T. Sasaki, J.W. Locasale, D.S. Auld, C.J. Thomas, M.G. Vander Heiden, and L.C. Cantley Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses Science 334 2011 1278 1283
53. M. Tamada, M. Suematsu, and H. Saya Pyruvate kinase M2: multiple faces for conferring benefits on cancer cells Clin. Cancer Res. 18 2012 5554 5561
54. M. Tamada, O. Nagano, S. Tateyama, M. Ohmura, T. Yae, T. Ishimoto, E. Sugihara, N. Onishi, T. Yamamoto, H. Yanagawa, M. Suematsu, and H. Saya Modulation of glucose metabolism by CD44 contributes to antioxidant status and drug resistance in cancer cells Cancer Res. 72 2012 1438 1448
55. J. Lee, H.K. Kim, Y.M. Han, and J. Kim Pyruvate kinase isozyme type M2 (PKM2) interacts and cooperates with Oct-4 in regulating transcription Int. J. Biochem. Cell Biol. 40 2008 1043 1054
56. H.J. Wang, Y.J. Hsieh, W.C. Cheng, C.P. Lin, Y.S. Lin, S.F. Yang, C.C. Chen, Y. Izumiya, J.S. Yu, H.J. Kung, and W.C. Wang JMJD5 regulates PKM2 nuclear translocation and reprograms HIF-1alpha-mediated glucose metabolism Proc. Natl. Acad. Sci. U.S.A. 111 2014 279 284
57. W. Yang, Y. Xia, D. Hawke, X. Li, J. Liang, D. Xing, K. Aldape, T. Hunter, W. Alfred Yung, and Z. Lu PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis Cell 150 2012 685 696
58. L. Lv, Y.-P. Xu, D. Zhao, F.-L. Li, W. Wang, N. Sasaki, Y. Jiang, X. Zhou, T.-T. Li, K.-L. Guan, Q.-Y. Lei, and Y. Xiong Mitogenic and oncogenic stimulation of K433 acetylation promotes PKM2 protein kinase activity and nuclear localization Mol. Cell 52 2013 340 352
59. Y. Jiang, X. Li, W. Yang, D.H. Hawke, Y. Zheng, Y. Xia, K. Aldape, C. Wei, F. Guo, Y. Chen, and Z. Lu PKM2 regulates chromosome segregation and mitosis progression of tumor cells Mol. Cell. 53 2013 75 87
60. K.E. Keller, Z.M. Doctor, Z.W. Dwyer, and Y.S. Lee SAICAR induces protein kinase activity of PKM2 that is necessary for sustained proliferative signaling of cancer cells Mol. Cell 53 2014 700 709
61. Y. Onodera, J.M. Nam, and M.J. Bissell Increased sugar uptake promotes oncogenesis via EPAC/RAP1 and O-GlcNAc pathways J. Clin. Investig. 124 2014 367 384
62. R. Hamanaka, and N. Chandel Targeting glucose metabolism for cancer therapy J. Exp. Med. 209 2012 211 215
63. D.A. Tennant, R.V. Duran, and E. Gottlieb Targeting metabolic transformation for cancer therapy Nat. Rev. Cancer 10 2010 267 277
64. M.G. Vander Heiden Targeting cancer metabolism: a therapeutic window opens Nat. Rev. Drug Discovery 10 2011 671 684
65. V. Gupta, K. Wellen, S. Mazurek, and R. Bamezai Pyruvate kinase M2: regulatory circuits and potential for therapeutic intervention Curr. Pharm. Des. 20 2014 2595 2606
66. M. Goldberg, and P. Sharp Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression J. Exp. Med. 209 2012 217 224
67. W. Guo, Y. Zhang, T. Chen, Y. Wang, J. Xue, Y. Zhang, W. Xiao, X. Mo, and Y. Lu Efficacy of RNAi targeting of pyruvate kinase M2 combined with cisplatin in a lung cancer model J. Cancer Res. Clin. Oncol. 137 2011 65 72
68. H.-S. Shi, D. Li, J. Zhang, Y.-S. Wang, L. Yang, H.-L. Zhang, X.-H. Wang, B. Mu, W. Wang, Y. Ma, F.-C. Guo, and Y.-Q. Wei Silencing of PKM2 increases the efficacy of docetaxel in human lung cancer xenografts in mice Cancer Sci. 101 2010 1447 1453
69. K. Bluemlein, N.-M. Grüning, R. Feichtinger, H. Lehrach, B. Kofler, and M. Ralser No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis Oncotarget 2 2011 393 400
70. B. Yoo, J.-L. Ku, S.-H. Hong, Y.-K. Shin, S. Park, H. Kim, and J.-G. Park Decreased pyruvate kinase M2 activity linked to cisplatin resistance in human gastric carcinoma cell lines Int. J. Cancer 108 2004 532 539
71. E. Martinez-Balibrea, C. Plasencia, A. Ginés, A. Martinez-Cardús, E. Musulén, R. Aguilera, J. Manzano, N. Neamati, and A. Abad A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines Mol. Cancer Ther. 8 2009 771 778
72. S.-L. Li, F. Ye, W.-J. Cai, H.-D. Hu, P. Hu, H. Ren, F.-F. Zhu, and D.-Z. Zhang Quantitative proteome analysis of multidrug resistance in human ovarian cancer cell line J. Cell. Biochem. 109 2010 625 633
73. Y.-K. Shin, B. Yoo, Y. Hong, H. Chang, K. Jung, S.-Y. Jeong, and J.-G. Park Upregulation of glycolytic enzymes in proteins secreted from human colon cancer cells with 5-fluorouracil resistance Electrophoresis 30 2009 2182 2192
74. M. Vander Heiden, H. Christofk, E. Schuman, A. Subtelny, H. Sharfi, E. Harlow, J. Xian, and L. Cantley Identification of small molecule inhibitors of pyruvate kinase M2 Biochem. Pharmacol. 79 2010 1118 1124
75. S. Müllner, H. Stark, P. Niskanen, E. Eigenbrodt, S. Mazurek, and H. Fasold From target to lead synthesis Proteomics in Drug Research 2006 Wiley-VCH Verlag GmbH & Co. KGaA 187 207
76. J. Chen, J. Xie, Z. Jiang, B. Wang, Y. Wang, and X. Hu Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2 Oncogene 30 2011 4297 4306
77. G.A. Spoden, U. Rostek, S. Lechner, M. Mitterberger, S. Mazurek, and W. Zwerschke Pyruvate kinase isoenzyme M2 is a glycolytic sensor differentially regulating cell proliferation, cell size and apoptotic cell death dependent on glucose supply Exp. Cell Res. 315 2009 2765 2774
78. M. Boxer, J.-K. Jiang, M. Vander Heiden, M. Shen, A. Skoumbourdis, N. Southall, H. Veith, W. Leister, C. Austin, H. Park, J. Inglese, L. Cantley, D. Auld, and C. Thomas Evaluation of substituted N,N′-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase J. Med. Chem. 53 2010 1048 1055
79. J.-K. Jiang, M. Boxer, M. Vander Heiden, M. Shen, A. Skoumbourdis, N. Southall, H. Veith, W. Leister, C. Austin, H. Park, J. Inglese, L. Cantley, D. Auld, and C. Thomas Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase Bioorg. Med. Chem. Lett. 20 2010 3387 3393
80. M. Walsh, K. Brimacombe, H. Veith, J. Bougie, T. Daniel, W. Leister, L. Cantley, W. Israelsen, M. Vander Heiden, M. Shen, D. Auld, C. Thomas, and M. Boxer 2-Oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase Bioorg. Med. Chem. Lett. 21 2011 6322 6327
81. M. Cortés-Cros, C. Hemmerlin, S. Ferretti, J. Zhang, J. Gounarides, H. Yin, A. Muller, A. Haberkorn, P. Chene, W. Sellers, and F. Hofmann M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth Proc. Natl. Acad. Sci. U.S.A. 110 2013 489 494
82. W.J. Israelsen, T.L. Dayton, S.M. Davidson, B.P. Fiske, A.M. Hosios, G. Bellinger, J. Li, Y. Yu, M. Sasaki, J.W. Horner, L.N. Burga, J. Xie, M.J. Jurczak, R.A. DePinho, C.B. Clish, T. Jacks, R.G. Kibbey, G.M. Wulf, D. Di Vizio, G.B. Mills, L.C. Cantley, and M.G. Vander Heiden PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells Cell 155 2013 397 409
83. D. Anastasiou, Y. Yu, W.J. Israelsen, J.K. Jiang, M.B. Boxer, B.S. Hong, W. Tempel, S. Dimov, M. Shen, A. Jha, H. Yang, K.R. Mattaini, C.M. Metallo, B.P. Fiske, K.D. Courtney, S. Malstrom, T.M. Khan, C. Kung, A.P. Skoumbourdis, H. Veith, N. Southall, M.J. Walsh, K.R. Brimacombe, W. Leister, S.Y. Lunt, Z.R. Johnson, K.E. Yen, K. Kunii, S.M. Davidson, H.R. Christofk, C.P. Austin, J. Inglese, M.H. Harris, J.M. Asara, G. Stephanopoulos, F.G. Salituro, S. Jin, L. Dang, D.S. Auld, H.W. Park, L.C. Cantley, C.J. Thomas, and M.G. Vander Heiden Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis Nat. Chem. Biol. 8 2012 839 847
84. A. Stetak, R. Veress, J. Ovadi, P. Csermely, G. Keri, and A. Ullrich Nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death Cancer Res. 67 2007 1602 1608
85. V. Gupta, P. Kalaiarasan, M. Faheem, N. Singh, M.A. Iqbal, and R.N. Bamezai Dominant negative mutations affect oligomerization of human pyruvate kinase M2 isozyme and promote cellular growth and polyploidy J. Biol. Chem. 285 2010 16864 16873
86. M.A. Iqbal, F.A. Siddiqui, N. Chaman, V. Gupta, B. Kumar, P. Gopinath, and R.N. Bamezai Missense mutations in pyruvate kinase m2 promote cancer metabolism, oxidative endurance, anchorage independence, and tumor growth in a dominant negative manner J. Biol. Chem. 289 2014 8098 8105
87. F. Hugo, G. Fischer, and E. Eigenbrodt Quantitative detection of tumor M2-PK in serum and plasma Anticancer Res. 19 1999 2753 2757
88. H.W. Wechsel, E. Petri, K.H. Bichler, and G. Feil Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK) Anticancer Res. 19 1999 2583 2590
89. B. Zhang, J.Y. Chen, D.D. Chen, G.B. Wang, and P. Shen Tumor type M2 pyruvate kinase expression in gastric cancer, colorectal cancer and controls World J. Gastroenterol. 10 2004 1643 1646
90. C. Tonus, M. Sellinger, K. Koss, and G. Neupert Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: a meta-analysis World J. Gastroenterol. 18 2012 4004 4011
91. Y.K. Shin, B.C. Yoo, Y.S. Hong, H.J. Chang, K.H. Jung, S.Y. Jeong, and J.G. Park Upregulation of glycolytic enzymes in proteins secreted from human colon cancer cells with 5-fluorouracil resistance Electrophoresis 30 2009 2182 2192
92. J. Schneider, K. Neu, H. Grimm, H.G. Velcovsky, G. Weisse, and E. Eigenbrodt Tumor M2-pyruvate kinase in lung cancer patients: immunohistochemical detection and disease monitoring Anticancer Res. 22 2002 311 318
93. H.F. Duan, X.W. Hu, J.L. Chen, L.H. Gao, Y.Y. Xi, Y. Lu, J.F. Li, S.R. Zhao, J.J. Xu, H.P. Chen, W. Chen, and C.T. Wu Antitumor activities of TEM8-Fc: an engineered antibody-like molecule targeting tumor endothelial marker 8 J. Natl Cancer Inst. 99 2007 1551 1555
94. I.F. Tannock Tumor physiology and drug resistance Cancer Metastasis Rev. 20 2001 123 132